Department of Ultrasound, the First Medical Center of Chinese People's Liberty Army General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, China.
School of Medicine, Nankai University, No. 94 Weijin Road, Nankai District, Tianjin, China.
Endocrine. 2024 Sep;85(3):1066-1074. doi: 10.1007/s12020-023-03660-9. Epub 2024 May 27.
To evaluate the safety and efficacy of radiofrequency ablation (RFA) in treating locoregional recurrent thyroid cancer (LRTC) after a 2-year follow-up time.
PubMed, Embase and Cochrane Library were searched from inception until 20 September 2022 to find studies reporting the safety and efficacy of RFA in LRTC patients after a 2-year follow-up. Two radiologists performed the data extraction and methodological quality assessment according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
We analyzed 6 studies, 229 LRTC patients with 319 locally recurrent tumors were treated with RFA. The mean follow-up time of each study was ≥24 months. The pooled changes in the largest diameter and volume were 7.22 mm (95% confidence interval (CI), 6.35-8.09 mm) and 164.28 mm (95% CI, 87.78-240.77 mm), respectively; the pooled volume reduction rate was 95.03% (95% CI, 87.56-102.49%). The total complete disappearance rate after treatment was 92% (95% CI, 83-100%). The pooled decrease of serum thyroglobulin levels was 0.02 ng/ml (95% CI, -0.00-0.04 ng/ml). The pooled proportion of recurrence rate was 6% (95% CI, 0-13%). The pooled complication rate was 5% (95% CI, 0-10%). The major complications were voice change and hoarseness, only one patient developed permanent vocal cord paralysis; minor complications were cough and pain.
Ultrasound-guided RFA is an effective and safe treatment for LRTC based on 2-year follow-up results.
评估射频消融（RFA）在 2 年随访后治疗局部复发性甲状腺癌（LRTC）的安全性和疗效。
从建库至 2022 年 9 月 20 日，检索 PubMed、Embase 和 Cochrane Library 以查找报告 RFA 在 2 年随访后治疗 LRTC 患者的安全性和疗效的研究。两名放射科医生根据系统评价和荟萃分析的首选报告项目指南进行数据提取和方法学质量评估。
我们分析了 6 项研究，共 229 例 LRTC 患者的 319 个局部复发性肿瘤接受了 RFA 治疗。每项研究的平均随访时间均≥24 个月。汇总的最大直径和体积变化分别为 7.22mm（95%置信区间[CI]，6.35-8.09mm）和 164.28mm（95%CI，87.78-240.77mm）；汇总的体积减少率为 95.03%（95%CI，87.56-102.49%）。治疗后总完全消失率为 92%（95%CI，83%-100%）。汇总的血清甲状腺球蛋白水平降低量为 0.02ng/ml（95%CI，-0.00-0.04ng/ml）。复发率的汇总比例为 6%（95%CI，0-13%）。汇总的并发症发生率为 5%（95%CI，0-10%）。主要并发症为声音改变和声音嘶哑，仅 1 例患者发生永久性声带麻痹；次要并发症为咳嗽和疼痛。
基于 2 年随访结果，超声引导下 RFA 是治疗 LRTC 的有效且安全的方法。
